Arrowhead Corp (ARWR): Fair Value Consensus

This daily price chart for Arrowhead Pharmaceuticals (ARWR) on the GURU.Markets platform, where the consensus forecast stands at 107.72, reflects the success of TRiM RNA technology for the targeted suppression of pathogenic genes. Business stability is supported by partnerships with industry behemoths that offset high R&D expenses. The monopoly potential of patents in hepatology allows Arrowhead Pharmaceuticals (ARWR) to expect premium pricing power for its future products.

ARWR arrowheadpharma.com: Price Target Chart in the range 07/04/2022 - 11/11/2026

Analytical breakdowns for Arrowhead Pharmaceuticals Inc (ARWR)

- stock value and consensus price forecast:

Stock Price arrowheadpharma.com|ARWR - Price Target Chart

- stock exchange capitalization data:

Market Value Arrowhead Pharmaceuticals Inc|ARWR - Real Price to Acquire Entire Company

- book capitalization indicators:

Accounting Value per Share Arrowhead Pharmaceuticals|ARWR - Company Book Value|Market Value to Book Value arrowheadpharma.com|ARWR - Aggregate Company Assets

- business debt structure and liquidity details:

Aggregate Debt to Equity Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Arrowhead Corp|ARWR - Company Aggregate Debts|Debts to Book Capitalization Arrowhead Pharmaceuticals Inc|ARWR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Arrowhead Pharmaceuticals|Quick Liquidity Indicator arrowheadpharma.com

- business earnings and investment ratios data:

ARWR - Net Profit|Projected Future Earnings Arrowhead Pharmaceuticals|ARWR - Price to Earnings Ratio|Future Price to Earnings Multiple Arrowhead Pharma|ARWR - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arrowhead Pharmaceuticals Inc|ARWR - Operating profit EBITDA|Net earnings per share for the last four quarters Arrowhead Pharmaceuticals|ARWR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months arrowheadpharma.com|ARWR - Earnings growth in current year|Expected net earnings per share growth next year Arrowhead Pharmaceuticals

General company analysis:ARWR arrowheadpharma.com

This indicator compares market expectations with actual financial results to assess the fair value of the asset. Daily recalculations capture the aggregate change in expert estimates, revealing the business's scaling potential. By analyzing the expert-projected share price, an investor determines whether the trend aligns with fundamental metrics. A divergence between charts signals a risk of overpayment. For Arrowhead Pharmaceuticals (ARWR), this reflects the success of RNA therapy development and the demand for its drugs among pharma behemoths.

Competitors of Arrowhead Pharmaceuticals